首页> 美国卫生研究院文献>Elsevier Public Health Emergency Collection >Cross-reactive antibodies in convalescent SARS patients sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests
【2h】

Cross-reactive antibodies in convalescent SARS patients sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests

机译:通过免疫荧光和中和抗体测试在康复的SARS患者血清中针对新兴的新型人类冠状病毒EMC(2012)的交叉反应抗体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A severe acute respiratory syndrome (SARS)-like disease due to a novel betacoronavirus, human coronavirus EMC (HCoV-EMC), has emerged recently. HCoV-EMC is phylogenetically closely related to -bat-coronavirus-HKU4 and -bat-coronavirus-HKU5 in Hong Kong. We conducted a seroprevalence study on archived sera from 94 game-food animal handlers at a wild life market, 28 SARS patients, and 152 healthy blood donors in Southern China to assess the zoonotic potential and evidence for intrusion of HCoV-EMC and related viruses into humans.
机译:由于新的β冠状病毒,人类冠状病毒EMC(HCoV-EMC),最近出现了一种严重的急性呼吸综合症(SARS)样疾病。 HCoV-EMC与香港的-bat-冠状病毒-HKU4和-bat-冠状病毒-HKU5在系统发育上密切相关。我们对来自野生动物市场的94位猎食动物处理者,28位SARS患者和152位健康献血者的存档血清进行了血清阳性率研究,以评估人畜共患病的潜力以及HCoV-EMC和相关病毒入侵的证据人类。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号